Real-world effectiveness of golimumab in the treatment of patients with active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who failed initial TNF-α inhibitor therapy: a pooled analysis of European prospective observational studies (the GO-BEYOND program)
Authors' conclusion
This pooled analysis of the GO-BEYOND studies showed that treatment with GLM was effective and represented a valid second-line option for RA, PsA, and axSpA patients.
Study context
- Population
- Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) who discontinued one prior TNFαi (loss of efficacy, tolerability or inconvenience), followed 12 months after golimumab (GLM) initiation, Europe
- Participants
- 712 patients6 observational studies
- Comparison
- RA vs PsA vs axSpA
- RAn = 325
- PsAn = 186
- axSpAn = 201
- Outcome
- Proportion achieving low disease activity (LDA) (DAS28-CRP<3.2) in RA, minimal disease activity (MDA) (5 of 7 outcome measures) in PsA, or low disease activity (ASDAS<2.1) in axSpA
- Follow-up
- 6 months
Methodological detailssix observational studies in Europe (GO-BEYOND program), observed-data analyses
- Six observational studies in Europe (GO-BEYOND program)
- Observed-data analyses
Pooled result
As reported in the abstract
Disease-specific primary endpoint achieved
Further pooled results
Disease activity at 3 and 12 months
- Disease activity improvements observed at 3 and 12 months
Quality of life (QoL) (EQ-5D-3L)
- Improved QoL over time
Treatment persistence · 12 months
- Treatment persistence rate
- 67.8%
Safety
Adverse events
- No new safety signals observed
Original publication
Real-world effectiveness of golimumab in the treatment of patients with active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who failed initial TNF-α inhibitor therapy: a pooled analysis of European prospective observational studies (the GO-BEYOND program). Clin Exp Rheumatol. Published 26 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →